---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-005799"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T18:52:12.342936+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eton launches Galzin (zinc acetate) capsules for Wilson disease maintenance therapy

## Summary
- Galzin is FDA-approved for maintenance treatment of Wilson disease after chelator therapy; only FDA-approved zinc therapy for Wilson disease.
- Exclusive distribution through Optime Care; Eton Cares program offers $0 co-pay, insurance benefits investigation, and educational support.
- CEO Sean Brynjelsen states dedicated sales force and patient support aim to expand access beyond unapproved compounded products.
- Eton is investing in further R&D to drive meaningful advancements in Wilson disease treatment.

## SEC filing metadata
- accession: 0001437749-25-005799
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774925005799/0001437749-25-005799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774925005799/eton20250225_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-005799
- JSON: https://secwatch.observer/filing/0001437749-25-005799.json
- Plain text: https://secwatch.observer/filing/0001437749-25-005799.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.